Skip to main content
NCBI home page
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2016 Sep;94(3):288. doi: 10.1016/j.contraception.2016.06.001

Corrigendum to “Rowe P et al. safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A” [Contraception 2016;93:498–506]

Patrick Rowe a, Tim Farley a, Alexandre Peregoudov a, Gilda Piaggio b, Simone Boccard a, Sihem Landoulsi c, Olav Meirik d,⁎; for the IUD Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction1
PMCID: PMC5357721  PMID: 27312266

We wish to make the following corrections to our article in the June 2016 issue of Contraception [1].

Page 498, first sentence of the Abstract should read: To compare rates of unintended pregnancy, method continuation and reasons for removal among women using the 52-mg levonorgestrel (daily release 20 microg) intrauterine device (LNG-IUD) or the copper T 380 A IUD (TCu380A).

Page 500, left column, first paragraph, first sentence should read: The trial was initially planned for at least 10 years of follow-up of use of the IUDs.

Page 504, right column, third paragraph, third sentence should read: The rate of discontinuation due to increased bleeding is slightly higher for the LNG-IUD than for the TCu380A in Chinese centres, while in non-Chinese centres, this pattern is reversed.

Reference

  • 1.Rowe P, Farley T, Peregoudov A, Piaggio G, Boccard S, Landoulsi S. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. Contraception. 2016;93:498–506. doi: 10.1016/j.contraception.2016.02.024. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES